HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

POM Decision Will Free FTC Resources For Other Enforcement

This article was originally published in The Tan Sheet

Executive Summary

With the POM Wonderful litigation off its desk, FTC will have more resources to bring cases against other advertisers, attorney Mark Ullman warns. Likely target areas in 2013 and beyond include social media marketing and more subtle disease claims.

You may also be interested in...



Demand For “Prediabetes” Supplements Exposes Marketing Risks

Navigating legally among claims for prediabetes or blood sugar levels is tricky. Experts discuss what keeps a claim legal and what crosses the line, and spotlight other disease categories that can get firms in trouble if claims are not crafted properly.

Updated FTC Dot Com Disclosures Guide Will Address Twitter, Blogs

The Federal Trade Commission soon will issue updated guidance about how endorsers and marketers should disclose financial relationships on blogs, Twitter and other social media platforms. The original guidance issued in 2000 was published before social networking boomed.

Judge Knocks Down FTC Substantiation Bar In POM Wonderful Case

An FTC administrative law judge says the agency cannot require randomized controlled trials to substantiate nutrient claims. POM Wonderful calls the decision “a huge win,” but the firm still received a cease-and-desist order for its pomegranate juice and supplement claims.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS124509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel